Clinical Research
Copyright ©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 7, 2007; 13(41): 5446-5453
Published online Nov 7, 2007. doi: 10.3748/wjg.v13.i41.5446
Table 1 Primers for NOD2 and NOD1 genotyping
ForwardReverseSize (bp)
NOD2
R702W5´-AGATCACAGCAGCCTTCCTG-3´5´-CACGCTCTTGGCCTCACC-3´185
G908R5´-CTCTTTTGGCCTTTTCAGATTCTG-3´5´-CAGCTCCTCCCTCTTCACCT-3´163
L1007finsC NOD15´-GGCAGAAGCCCTCCTGCAGGGCC-3´5´-CCTCAAAATTCTGCCATTCC-3´151
ND1+326565´-TGACTGTGTGTGACTCTCTCTGC-3´5´-TGGTGAAAGCTCTCCACTATCTC-3´250
Table 2 Genotype at NOD2 polymorphisms in CD cases and healthy controls
MutationGroupGenotype count, n (%)
OR (95% CI)1P2
WT/WTHeterozygousHomozygous
R702WCD75 (77.32)21 (21.65)1 (1.03)7.04 (1.58-31.30)0.004
Controls48 (96.00)2 (4.00)0
G908RCD92 (94.85)5 (5.15)00.166
Controls50 (100)00
L1007finsCCD89 (91.75)8 (8.25)04.40 (0.53-36.25)0.167
Controls49 (98.00)1 (2.00)0
Table 3 Distribution of NOD2 mutations in CD patients and controls
NOD2 genotypeCD Patients,n (%)Controls,n (%)OR (95% CI)1P2
At least one variant330 (30.92)3 (6)7.01 (2.02-24.30)< 0.001
Heterozygous24 (24.74)3 (6)5.61 (1.59-19.0)0.003
Compound heterozygous45 (5.15)0
Homozygous1 (1.03)0
Table 4 Genotype frequencies of ND1+32656 in CD patients and controls
GroupNOD2n1NOD1 genotype, n (%)
*1*1*1*2*2*2
CD9758 (59.79)236 (37.11)3 (3.09)
WT/WT6740 (59.70)25 (37.31)2 (2.98)
Mutant33018 (60.00)11 (36.66)1 (3.33)
Controls5026 (52.00)17 (34.00)7 (14.00)
WT/WT4723 (48.93)17 (36.17)7 (14.89)
Mutant33 (100)00
Table 5 Clinical characteristics of CD patients according to NOD2 genotype
Clinical featuresn1NOD2 genotype, n (%)
P2OR (95% CI)
WT/WTR702W/WTG908R/WTL1007fsinsC/WTHeter.compound & homozygous
Age at diagnosis
< 40 yr (A1 + A2)8054 (55.67)313 (13.40)3 (3.09)4 (4.12)6 (6.18)0.57 1.56 (0.46-5.27)
> 40 yr (A3)1713 (13.40)3 (3.09)01 (1.03)0
Location
Ileal (L1)3421 (21.65)8 (8.25)1 (1.03)2 (2.06)2 (2.06)0.26 1.67 (0.69-4.06)
Colonic (L2)2320 (20.62)01 (1.03)1 (1.03)1 (1.03)0.04 0.26 (0.07-0.96)
Ileocolonic (L3)4026 (26.80)8 (8.25)1 (1.03)2 (2.06)3 (3.09)0.5 1.38 (0.57-3.29)
Behavior
Non-stricturing, non-penetrating (B1)3724 (24.74)8 (8.25)3 (3.09)2 (2.06)00.5 1.37 (0.56-3.29)
Stricturing (B2)4134 (35.05)5 (5.15)002 (2.06)0.01 0.29 (0.11-0.78)
Penetrating (B3)199 (9.28)3 (3.09)03 (3.09)4 (4.12)0.02 3.22 (1.14-9.06)
Table 6 Clinical characteristics of NOD2 WT/WT CD patients according to NOD1 genotype
Clinical featuresn1NOD2 WT/WT
NOD1:*1*1*1*2*2*2
Age at diagnosis
< 40 yr (A1 + A2)5462.96235.181.85
> 40 yr (A3)1346.1546.157.69
Location
Ileal (L1)2157.1438.094.76
Colonic (L2)2070255
Ileocolonic (L3)2653.8446.150
Behavior
Non-stricturing,2462.533.334.16
non-penetrating (B1)
Stricturing (B2)3461.7635.292.94
Penetrating (B3)944.4455.550
Controls4748.9336.1714.89